May 31, 2014

MMRF Newsflash from ASCO 2014 - Volume 1


Welcome to our first day of on-site coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

Yesterday, there were several poster presentations featuring novel therapies in early stage development which showed promising activity in patients with relapsed/refractory multiple myeloma, many of whom had failed not only Velcade and Revlimid but also Kyprolis and Pomalyst. New drugs included two monoclonal antibodies, SAR650984 (which has been in studied in the MMRC, our clinical network) and daratumumab as well as a new formulation of chemotherapy, TH-302.

  • 24% of patients who had been previously treated with an average of six prior therapies responded to SAR650984. Further, myeloma was controlled in another 41% of patients. Data from an MMRC trial which studied SAR650984 in combination with Rev-dex will be presented on Monday.

  • 75% of patients responded to the combination of daratumumab and Revlimid-dex. Two Phase III studies evaluating this drug are expected to begin soon.

Further, a response rate of 53% was seen using a four drug regimen including Revlimid-dex, Kyprolis and Zolinza. However, there were significant reductions in blood counts in some of these patients. Zolinza is FDA approved for a type of lymphoma, so it could be used on an “off-label” basis for some myeloma patients. Data on a related compound in the same class, panobinostat, will be presented during an oral presentation session on Monday.

Stay tuned for further updates on Monday where there is an oral and another poster session!

MMRF ASCO Coverage

To see the full MMRF coverage from ASCO with ongoing updates, please visit: www.themmrf.org/asco.